China’s Tech Advances: AI, Drug Trials, Cell Breakthrough
China has showcased its expanding technological capabilities across three distinct frontiers on June 24, 2026, with new data revealing its AI large language models maintaining a commanding global lead in token call volume, its pharmaceutical industry setting a national record for clinical trials, and researchers achieving a world-first breakthrough in artificial cell technology.
AI Token Call Volume: China Extends Global Lead
Chinese AI large language models generated 18.81 trillion token calls during the week of June 15-21, 2026, marking the eighth consecutive week that China has ranked first globally, according to data from OpenRouter reported by People’s Daily. Global total token calls reached 46.7 trillion for the week, rising for nine straight weeks.
By comparison, the United States recorded 5.76 trillion weekly token calls — roughly one-third of China’s volume — with week-over-week growth of just 0.70%. China’s token call volume grew 2.12% week-over-week, extending a four-week growth streak.
Competitive Landscape Heats Up
Among individual models, DeepSeek-V4-Flash held the top spot for the fifth consecutive week with 4.94 trillion weekly token calls, up 12% week-over-week. Xiaomi’s MiMo-V2.5 surged from fourth to second place with 3.94 trillion calls, while MiniMax M3 slipped to third at 3.77 trillion. Tencent’s Hy3preview dropped out of the top three for the first time in two months, falling to fourth with 3.63 trillion calls.
Industry analysts cited by Securities Daily said the data signals that China’s AI industry has moved beyond the initial “hundred-model war” and parameter-scale competition into a phase centered on large-scale application and value realization. Zhang Yi, CEO of iiMedia Consulting, noted that token call volume “is not simply a number increase, but a true microcosm of AI industry implementation capability.”
Market Consolidation Signals Maturity
China’s AI large model ecosystem now comprises approximately 13,000 enterprises, but new registrations have slowed dramatically — just 24 in 2026 year-to-date compared to 395 in all of 2025, indicating market rationalization. Over 75% of enterprises are concentrated in first-tier and new first-tier cities, and 44.52% have registered capital of 50 million yuan or more, reflecting high barriers to entry.
Drug Clinical Trials Surpass 5,000 for First Time
China’s pharmaceutical sector reached a historic milestone in 2025, with total drug clinical trials exceeding 5,000 for the first time, according to the annual report released on June 22 by the National Medical Products Administration (NMPA) Center for Drug Evaluation, as reported by People’s Daily.
Record-Breaking Numbers
The 2025 total of 5,215 clinical trials represents a steady upward trajectory: 4,300 in 2023 (first time above 4,000), 4,900 in 2024 (up 13.9%), and now the new record. Of the 2025 total, 2,997 were new drug clinical trials (57.5%, up 18% year-over-year), while 2,218 were bioequivalence trials.
A total of 248 new drugs were approved through clinical trials, covering 18 therapeutic areas including oncology, endocrinology, and psychiatric disorders. Yang Zhimin, Deputy Director of the NMPA Drug Evaluation Center, confirmed the breadth of approvals.
Accelerated Timelines
The NMPA report highlighted significant efficiency gains: the average startup time for clinical trials was shortened by four months year-over-year, with 1,088 new drug trials signing their first-subject informed consent in 2025. Drug registration applications reviewed reached 19,375, up 6.11% year-over-year — also a record high.
The NMPA stated that China’s clinical trial technical guidelines are aligned with international standards, gradually promoting mutual recognition of clinical data and results across borders. International multi-center clinical trials accounted for 410 of the annual total (13.7%), underscoring China’s growing integration into global drug development.
Artificial Cells Achieve Asymmetric ‘Shape-Shifting’ Breakthrough
In a development that bridges chemistry, materials science, and synthetic biology, researchers at the Chinese Academy of Sciences (CAS) Institute of Chemistry have achieved the first-ever asymmetric division of artificial cells — both in morphology and function — with results published in the journal Nature on May 13, 2026, as reported by Xinhua News.
A ‘Peeling-Off’ Process
The research team, led by Qiao Yan and Wang Shu in collaboration with domestic and international scientists, used a novel structured liquid droplet model as a starting point to achieve what Qiao described as a “peeling-off” (剥离式) asymmetric division process. This differs fundamentally from previous symmetric division methods and occurs extremely rapidly, challenging the limits of instrument capture capabilities.
Implications for Biomanufacturing
Asymmetric division is a fundamental property of stem cells, which produce both new stem cells and functional daughter cells. Replicating this process in artificial cells opens new directions in biomanufacturing and deepens understanding of life-like functional emergence and protocell research. The breakthrough fills a long-standing technical gap at the intersection of multiple scientific disciplines.
Broader Implications
Taken together, these three advances paint a picture of a technology ecosystem maturing across multiple dimensions simultaneously. China’s AI sector is transitioning from breakneck expansion to quality-focused development, its pharmaceutical industry is accelerating drug development through regulatory efficiency and growing global integration, and its fundamental research in synthetic biology is earning international recognition through publications in top-tier journals.
What to Watch
Looking ahead, key questions include how China’s AI market consolidation will affect innovation velocity, whether the clinical trial acceleration will translate into faster drug approvals for patients, and what practical applications will emerge from the artificial cell breakthrough in fields such as biomanufacturing and regenerative medicine.